Natalie Clayton's practice focuses on resolution of intellectual property disputes. She has extensive experience litigating intellectual property matters involving a wide range of legal issues. Natalie has represented clients in trials throughout the United States, and has particular expertise in Hatch-Waxman cases. She has been involved in patent cases covering diverse areas of technology, including pharmaceuticals, software, chemical, medical devices and mechanical devices. Natalie has represented clients in the pharmaceutical and gemological industries in trademark, false advertising and unfair competition cases brought under the Lanham Act. Natalie is also experienced in patent opinion practice, conducting due diligence investigations, reexamination proceedings and FDA regulatory matters involving pharmaceuticals and dietary ingredients.
Natalie is a member of the American and New York Bar Associations. She actively participates in several pro bono projects, including representing Sustainable Health Enterprises, a non-profit organization that seeks to bring market-based solutions to developing countries.
- Counsel to some of the world’s leading generic pharmaceutical companies.
- Counsel to one of the world’s leading pharmaceutical and chemical specialty companies.
- Counsel to one of the world’s largest providers of financial management and trading software solutions.
- Counsel to one of the world's leading gemological grading companies.
-
A complete victory for our client, Merck & Cie! On January 31, 2013, the Hon. R.J. Sullivan of the Southern District of New York issued his decision regarding this matter that went to trial in 2011—and it was well worth the wait!
January 31, 2013
In the Press
-
Alston & Bird is pleased to announce that the following individuals have been named partners in the firm effective January 1, 2013:
January 2, 2013
In the Press
-
Robert Hanlon, Thomas Parker, Natalie Clayton, Victoria Spataro and Lance Soderstrom, based in the firm’s New York office, received a favorable opinion on behalf of their client, Merck & Cie—a producer of pharmaceutical and dietary ingredients—in response to their action against Gnosis S.p.A. and Gnosis BioResearch S.A. for false advertising in connection with Gnosis’s manufacture and sale of a folate nutritional ingredient, which competes with Merck’s product, Metafolin®.
November 30, 2012
In the Press